415 related articles for article (PubMed ID: 31009585)
1. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
Sano M; Goto S
Circulation; 2019 Apr; 139(17):1985-1987. PubMed ID: 31009585
[No Abstract] [Full Text] [Related]
2. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
[TBL] [Abstract][Full Text] [Related]
3. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
Sattar N; McGuire DK
Circulation; 2018 Jul; 138(1):7-9. PubMed ID: 29967228
[No Abstract] [Full Text] [Related]
4. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
5. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
6. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC; Vallon V
Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
[TBL] [Abstract][Full Text] [Related]
7. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD
J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290
[TBL] [Abstract][Full Text] [Related]
8. Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Packer M
Am J Nephrol; 2020; 51(4):289-293. PubMed ID: 32126558
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
10. Effect of SGLT2 inhibitors on anemia and their possible clinical implications.
Cases A; Cigarrán S; Luis Górriz J; Nuñez J
Nefrologia (Engl Ed); 2024; 44(2):165-172. PubMed ID: 38604895
[TBL] [Abstract][Full Text] [Related]
11. Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease.
Speedtsberg ES; Tepel M
Front Endocrinol (Lausanne); 2023; 14():1281107. PubMed ID: 38174341
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
Zelniker TA; Braunwald E
J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
[TBL] [Abstract][Full Text] [Related]
13. Research digest: new horizons in heart failure therapy.
Sattar N; Preiss D
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):832. PubMed ID: 31621593
[No Abstract] [Full Text] [Related]
14. Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells.
Morita M; Kanasaki K
Diabetes Metab; 2020 Oct; 46(5):353-361. PubMed ID: 32891754
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation.
Sano M
Ther Adv Cardiovasc Dis; 2020; 14():1753944720939383. PubMed ID: 32715944
[TBL] [Abstract][Full Text] [Related]
16. Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?
Ekanayake P; Mudaliar S
Diabetes Metab Syndr; 2023 Feb; 17(2):102702. PubMed ID: 36657305
[TBL] [Abstract][Full Text] [Related]
17. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.
Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537
[No Abstract] [Full Text] [Related]
18. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
Sano M
J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
Reid T
J Fam Pract; 2021 Jul; 70(6S):S1-S6. PubMed ID: 34432617
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
